Profile data is unavailable for this security.
About the company
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-4.13m
- Incorporated2005
- Employees2.00
- LocationLixte Biotechnology Holdings Inc433 Plaza Real, Suite 275BOCA RATON 33432United StatesUSA
- Phone+1 (310) 203-2902
- Fax+1 (928) 982-5050
- Websitehttps://lixte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kairos Pharma Ltd | 0.00 | -5.06m | 13.35m | 1.00 | -- | 1.74 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| Cadrenal Therapeutics Inc | 0.00 | -14.39m | 13.58m | 4.00 | -- | 4.38 | -- | -- | -7.82 | -7.82 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -328.18 | -- | -468.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.45 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 13.73m | 1.00 | -- | 1.04 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| Vyome Holdings Inc | 4.19m | -11.35m | 14.51m | 17.00 | -- | 5.64 | -- | 3.46 | -182.98 | -182.98 | 5.45 | 0.4553 | 0.6626 | -- | 6.14 | 246,742.90 | -181.86 | -143.74 | -557.79 | -202.53 | 62.39 | 61.09 | -274.45 | -325.23 | -- | -- | 0.00 | -- | -7.74 | 19.53 | 37.38 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -15.31m | 14.96m | 6.00 | -- | 1.25 | -- | -- | -2.31 | -2.31 | 0.00 | 0.7455 | 0.00 | -- | -- | 0.00 | -74.37 | -62.78 | -122.61 | -113.20 | -- | -- | -- | -- | -- | -- | 0.1037 | -- | -- | -- | -23.21 | -- | 106.17 | -- |
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 15.34m | 2.00 | -- | 6.50 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 15.42m | 7.00 | 0.0683 | 3.03 | -- | 5.42 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 15.64m | 360.00 | -- | -- | -- | 0.0108 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| NuCana PLC (ADR) | 0.00 | -37.54m | 15.99m | 20.00 | -- | 0.4522 | -- | -- | -7,207.90 | -7,207.90 | 0.00 | 4.93 | 0.00 | -- | -- | 0.00 | -106.16 | -47.75 | -180.13 | -58.87 | -- | -- | -- | -- | -- | -1.59 | 0.0052 | -- | -- | -- | 31.25 | -- | -25.32 | -- |
| Iterum Therapeutics PLC | 390.00k | -26.96m | 16.36m | 9.00 | -- | -- | -- | 41.95 | -0.7488 | -0.7488 | 0.0107 | -0.1507 | 0.0161 | -- | 0.9512 | 43,333.33 | -111.35 | -99.44 | -231.48 | -169.64 | 94.87 | -- | -6,913.08 | -- | 1.96 | -3.43 | 1.28 | -- | -- | -- | 35.44 | -- | -39.16 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -37.43m | 16.85m | 23.00 | -- | 0.217 | -- | -- | -3.84 | -3.84 | 0.00 | 3.74 | 0.00 | -- | -- | 0.00 | -32.10 | -29.86 | -52.00 | -35.19 | -- | -- | -- | -- | 0.1257 | -244.30 | 0.0127 | -- | -- | -- | 6.85 | -- | 400.55 | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 17.13m | 3.00 | -- | 1.65 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| Linike Medical Group Ltd | 0.00 | -306.90k | 17.16m | -- | -- | -- | -- | -- | -0.1102 | -0.1102 | 0.00 | -0.153 | 0.00 | -- | -- | -- | -278.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -651.26 | -- | -- | -- |
| Pasithea Therapeutics Corp | 0.00 | -13.49m | 17.27m | 4.00 | -- | 0.4562 | -- | -- | -5.21 | -5.21 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -83.64 | -- | -89.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.34 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Lixte Biotechnology Holdings Inc's reporting currency: US Dollar USD
4.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 30 Sep 2025 | 73.15k | 0.91% |
| Desjardins Securities, Inc.as of 30 Sep 2025 | 50.85k | 0.64% |
| DRW Securities LLCas of 30 Sep 2025 | 48.48k | 0.61% |
| Geode Capital Management LLCas of 30 Sep 2025 | 41.44k | 0.52% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 39.91k | 0.50% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 35.03k | 0.44% |
| Ethos Financial Group LLCas of 31 Dec 2025 | 24.81k | 0.31% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 17.40k | 0.22% |
| Atlas Legacy Advisors LLCas of 31 Dec 2025 | 13.77k | 0.17% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 3.00k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
